ZNTL (Zentalis Pharmaceuticals) Tariff Resilience Score: 5/10 (As of Jul. 08, 2026)


ZNTL Zentalis Pharmaceuticals Inc ZNTL
30 GF Score
Price $4.86
! 3 Warning Signs
View Full Analysis

What is Zentalis Pharmaceuticals Tariff Resilience Score?

Zentalis Pharmaceuticals ZNTL +1.57% 30 Tariff Resilience Score is 5 as of Jul. 08, 2026. GuruFocus rates ZNTL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,367 Biotechnology companies, Zentalis Pharmaceuticals ranks better than 62.4% on this metric.

Zentalis Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Zentalis Pharmaceuticals has Zentalis relies on global supply chains for raw materials and manufacturing. While the pharmaceutical industry often has tariff exemptions, any changes could impact costs. The company has some pricing power but limited alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zentalis Pharmaceuticals might have Average Resilient.

Zentalis Pharmaceuticals  (NAS:ZNTL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zentalis Pharmaceuticals Tariff Resilience Score Related Terms

ZNTL vs ELDN, GLSI, SABS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Zentalis Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zentalis Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's Tariff Resilience Score falls into.


ZNTL
30GF Score
Zentalis Pharmaceuticals Inc ZNTL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Zentalis Pharmaceuticals (ZNTL) has a Tariff Resilience Score of 5 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Zentalis Pharmaceuticals ranks #514 out of 1367 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Zentalis Pharmaceuticals' Tariff Resilience Score too high?
Zentalis Pharmaceuticals' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Zentalis Pharmaceuticals' value of 5 is 25% above this industry median. Based on the distribution chart, Zentalis Pharmaceuticals ranks #514 out of 1367 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zentalis Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zentalis Pharmaceuticals' Tariff Resilience Score compare to ELDN and GLSI?
According to the Biotechnology industry distribution chart, Zentalis Pharmaceuticals ranks #514 out of 1367 companies for Tariff Resilience Score. This puts Zentalis Pharmaceuticals in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Zentalis Pharmaceuticals' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zentalis Pharmaceuticals's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zentalis Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentalis Pharmaceuticals stock overvalued right now?
Zentalis Pharmaceuticals (ZNTL) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Zentalis Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Zentalis Pharmaceuticals (ZNTL), the current Tariff Resilience Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zentalis Pharmaceuticals Business Description

Address 10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
30GF Score

Get the complete analysis for ZNTL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.86
Price